{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:55:50Z","timestamp":1760622950731,"version":"3.41.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,5,17]],"date-time":"2015-05-17T00:00:00Z","timestamp":1431820800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s00408-015-9742-6","type":"journal-article","created":{"date-parts":[[2015,5,16]],"date-time":"2015-05-16T12:23:35Z","timestamp":1431779015000},"page":"467-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Lymphangioleiomyomatosis: New Treatment Perspectives"],"prefix":"10.1007","volume":"193","author":[{"given":"El\u017cbieta","family":"Radzikowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,17]]},"reference":[{"key":"9742_CR1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1164\/rccm.200409-1298OC","volume":"173","author":"JH Ryu","year":"2006","unstructured":"Ryu JH, Moss J, Beck GJ et al (2006) The NHLBI lymphangioleiomyomatosis registry. Characteristics of 230 patients at enrolment. Am J Respir Crit Care Med 173:105\u2013111. doi: 10.1164\/rccm.200409-1298OC","journal-title":"Am J Respir Crit Care Med"},{"key":"9742_CR2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00408-012-9419-3","volume":"191","author":"N Oprescu","year":"2013","unstructured":"Oprescu N, McCormack FX, Byrnes S, Kinder BW (2013) Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry. Lung 191:35\u201342. doi: 10.1007\/s00408-012-9419-3","journal-title":"Lung"},{"key":"9742_CR3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1183\/09031936.00076209","volume":"35","author":"SR Jonhson","year":"2010","unstructured":"Jonhson SR, Cordier J-F, Lazor R et al (2010) Review panel of the ERS LAM Task Force. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 35:14\u201326. doi: 10.1183\/09031936.00076209","journal-title":"Eur Respir J"},{"key":"9742_CR4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup H, Krueger DA, On behalf of International Tuberous Sclerosis Complex Consensus Group (2013) Tuberous sclerosis complex consensus diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol 49:243\u2013254. doi: 10.1016\/j.pediatrneurol.2013.08.001","journal-title":"Pediatr Neurol"},{"key":"9742_CR5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/s-0030-1269906","volume":"41","author":"DN Franz","year":"2010","unstructured":"Franz DN, Bissler JJ, McCormack FX (2010) Tuberous sclerosis complex: neurological, renal and pulmonary manifestations. Neuropediatrics 41:199\u2013208. doi: 10.1055\/s-0030-1269906","journal-title":"Neuropediatrics"},{"key":"9742_CR6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.4065\/75.6.591","volume":"75","author":"LC Costello","year":"2000","unstructured":"Costello LC, Hartman TE, Ryu JH (2000) High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc 75:591\u2013594","journal-title":"Mayo Clin Proc"},{"key":"9742_CR7","first-page":"163","volume":"14","author":"JH Ryu","year":"2012","unstructured":"Ryu JH, Hartman TE, Torres VE, Decker PA (2012) Frequency of undiagnosed cystic lung disease in patients with sporadic renal angiomyolipomas. Chest 14:163\u2013168. doi: 10.1378\/chest.11-0669","journal-title":"Chest"},{"key":"9742_CR8","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1378\/chest.12-2813","volume":"144","author":"CJ Cudzi\u0142o","year":"2013","unstructured":"Cudzi\u0142o CJ, Szczesniak RD, Brody AS et al (2013) Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest 144:578\u2013585. doi: 10.1378\/chest.12-2813","journal-title":"Chest"},{"key":"9742_CR9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1148\/radiology.214.2.r00fe41441","volume":"214","author":"NA Avila","year":"2000","unstructured":"Avila NA, Chen CC, Chu SC et al (2000) Pulmonary lymphangioleiomyomatosis: correlation of ventilation-perfusion scintigraphy, chest radiography, and CT with pulmonary function tests. Radiology 214:441\u2013446","journal-title":"Radiology"},{"key":"9742_CR10","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.2353\/ajpath.2009.080830","volume":"175","author":"RB Issaka","year":"2009","unstructured":"Issaka RB, Oommen S, Gupta SK et al (2009) Vascular endothelial growth factors C and D induce proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium. Am J Pathol 175:1410\u20131420. doi: 10.2353\/ajpath.2009.080830","journal-title":"Am J Pathol"},{"key":"9742_CR11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/lrb.2006.4.143","volume":"4","author":"K Seyama","year":"2006","unstructured":"Seyama K, Kumasaka T, Souma S et al (2006) Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol 4:143\u2013152. doi: 10.1089\/lrb.2006.4.143","journal-title":"Lymphat Res Biol"},{"key":"9742_CR12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1056\/NEJMc0707517","volume":"358","author":"LR Young","year":"2008","unstructured":"Young LR, Inoue Y, McCormack FX (2008) Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Eng J Med 358:199\u2013200. doi: 10.1056\/NEJMc0707517","journal-title":"N Eng J Med"},{"key":"9742_CR13","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1378\/chest.10-0573","volume":"138","author":"LR Young","year":"2010","unstructured":"Young LR, VanDyke R, Gulleman PM et al (2010) Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 138:674\u2013681. doi: 10.1378\/chest.10-0573","journal-title":"Chest"},{"key":"9742_CR14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1378\/chest.08-1160","volume":"135","author":"CG Glasgow","year":"2009","unstructured":"Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J (2009) Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 135:1293\u20131300. doi: 10.1378\/chest.08-1160","journal-title":"Chest"},{"key":"9742_CR15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1465-9921-13-34","volume":"13","author":"WYC Chang","year":"2012","unstructured":"Chang WYC, Cane JL, Blakey JD, Kumaran M, Pointon KS, Johnson SR (2012) Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Respir Res 13:34. doi: 10.1186\/1465-9921-13-34","journal-title":"Respir Res"},{"key":"9742_CR16","doi-asserted-by":"crossref","first-page":"533","DOI":"10.20452\/pamw.1927","volume":"123","author":"E Radzikowska","year":"2013","unstructured":"Radzikowska E, Jagu\u015b P, Skoczylas A et al (2013) Role of serum vascular endothelial growth factor D in discrimination of patients with polycystic lung diseases. Pol Arch Med Wewn 123:533\u2013538","journal-title":"Pol Arch Med Wewn"},{"key":"9742_CR17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.rmed.2012.10.006","volume":"107","author":"KF Xu","year":"2013","unstructured":"Xu KF, Zhang P, Tian X et al (2013) The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM). Respir Med 107:263\u2013268. doi: 10.1016\/j.rmed.2012.10.006","journal-title":"Respir Med"},{"key":"9742_CR18","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00408-014-9641-2","volume":"192","author":"BG Baldi","year":"2014","unstructured":"Baldi BG, Araujo MS, Freitas CS et al (2014) Evaluation of the extent of pulmonary Cysts and Their association with functional variables and serum markers in lymphangioleiomyomatosis (LAM). Lung 192:967\u2013974. doi: 10.1007\/s00408-014-9641-2","journal-title":"Lung"},{"key":"9742_CR19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/jmg.37.1.55","volume":"37","author":"A Astrinidis","year":"2000","unstructured":"Astrinidis A, Khare L, Carsillo T et al (2000) Mutational analysis of tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis. J Med Genet 37:55\u201357. doi: 10.1136\/jmg.37.1.55","journal-title":"J Med Genet"},{"key":"9742_CR20","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.277.5327.805","volume":"277","author":"M Slegtenhorst van","year":"1997","unstructured":"van Slegtenhorst M, de Hoogt R, Hermans C et al (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277:805\u2013808. doi: 10.1126\/science.277.5327.805","journal-title":"Science"},{"key":"9742_CR21","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","volume":"75","author":"European Chromosome 16 Tuberous Sclerosis Consortium","year":"1993","unstructured":"European Chromosome 16 Tuberous Sclerosis Consortium (1993) Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75:1305\u20131315. doi: 10.1016\/0092-8674(93)90618-Z","journal-title":"Cell"},{"key":"9742_CR22","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.ejhg.5201402","volume":"13","author":"O Sancak","year":"2005","unstructured":"Sancak O, Nellist M, Goedbloed M et al (2005) Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype: phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur J Hum Genet 13:731\u2013741. doi: 10.1038\/sj.ejhg.5201402","journal-title":"Eur J Hum Genet"},{"key":"9742_CR23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/BJ20080281","volume":"412","author":"J Huang","year":"2008","unstructured":"Huang J, Manning BD (2008) The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 412:179\u2013190. doi: 10.1042\/BJ20080281","journal-title":"Biochem J"},{"key":"9742_CR24","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1164\/ajrccm.164.4.2011025","volume":"164","author":"DN Franz","year":"2001","unstructured":"Franz DN, Brody A, Meyer C et al (2001) Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med 164:661\u2013668. doi: 10.1164\/ajrccm.164.4.2011025","journal-title":"Am J Respir Crit Care Med"},{"key":"9742_CR25","doi-asserted-by":"crossref","first-page":"e24919","DOI":"10.1371\/journal.pone.0024919","volume":"6","author":"W Qin","year":"2011","unstructured":"Qin W, Bajaj V, Malinowska I et al (2011) Angiomyolipoma have common mutations in TSC2 but no other common genetic events. PLoS ONE 6:e24919. doi: 10.1371\/journal.pone.0024919","journal-title":"PLoS ONE"},{"key":"9742_CR26","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1086\/301804","volume":"62","author":"TA Smolarek","year":"1998","unstructured":"Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP (1998) Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 62:810\u2013815. doi: 10.1086\/301804","journal-title":"Am J Hum Genet"},{"key":"9742_CR27","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1073\/pnas.97.11.6085","volume":"97","author":"T Carsillo","year":"2000","unstructured":"Carsillo T, Astrinidis A, Henske EP (2000) Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 97:6085\u20136090","journal-title":"Proc Natl Acad Sci USA"},{"key":"9742_CR28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/jmg.37.1.55","volume":"37","author":"A Astrinidis","year":"2014","unstructured":"Astrinidis A, Khare L, Carsillo T et al (2014) Mutational analysis of the tuberous sclerosis geneTSC2 in patients with pulmonary lymphangioleiomyomatosis. J Med Genet 37:55\u201357. doi: 10.1136\/jmg.37.1.55","journal-title":"J Med Genet"},{"key":"9742_CR29","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1164\/ajrccm.187.6.663","volume":"187","author":"KR Badri","year":"2013","unstructured":"Badri KR, Gao L, Hyjek E et al (2013) Exonic mutations of TSC2\/TSC1 are common but not seen in all sporadic pulmonary lymphangioleiomyomatosis. Am J Respir Crit Care Med 187:663\u2013665. doi: 10.1164\/ajrccm.187.6.663","journal-title":"Am J Respir Crit Care Med"},{"key":"9742_CR30","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1172\/JCI58709","volume":"122","author":"EP Henske","year":"2012","unstructured":"Henske EP, McCormack FX (2012) Lymphangioleiomyomatosis\u2014a wolf in sheep\u2019s clothing. J Clin Invest 122:3807\u20133816. doi: 10.1172\/JCI58709","journal-title":"J Clin Invest"},{"key":"9742_CR31","author":"Y Sun","year":"2014","unstructured":"Sun Y, Gu X, Zhang E et al (2014) Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in TORC1 hyperactive cells. Cell Death Dis. doi: 10.1038\/cddis.2014.204","journal-title":"Cell Death Dis"},{"key":"9742_CR32","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s12672-014-0192-z","volume":"5","author":"Y Sun","year":"2014","unstructured":"Sun Y, Zhang E, Lao T et al (2014) Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosis. Horm Cancer 5:284\u2013298. doi: 10.1007\/s12672-014-0192","journal-title":"Horm Cancer"},{"key":"9742_CR33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1165\/rcmb.2012-0476OC","volume":"49","author":"C Li","year":"2013","unstructured":"Li C, Zhou X, Sun Y et al (2013) Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 49:135\u2013142. doi: 10.1165\/rcmb.2012-0476OC","journal-title":"Am J Respir Cell Mol Biol"},{"key":"9742_CR34","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1164\/ajrccm.160.2.9901027","volume":"160","author":"S Johnson","year":"1999","unstructured":"Johnson S, Tattersfield E (1999) Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med 160:628\u2013633. doi: 10.1164\/ajrccm.160.2.9901027","journal-title":"Am J Respir Crit Care Med"},{"key":"9742_CR35","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1378\/chest.126.6.1867","volume":"126","author":"AM Taveira-Dasilva","year":"2004","unstructured":"Taveira-Dasilva AM, Stylianou MP, Hedin CJ et al (2004) Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 126:1867\u20131874. doi: 10.1378\/chest.126.6.1867","journal-title":"Chest"},{"key":"9742_CR36","doi-asserted-by":"crossref","unstructured":"Harari S, Cassandro R, Chiodini I, Taveira-DaSilva AM, Moss J (2008) Effect of a gonadotropin-releasing hormone analogue on lung function in lymphangioleiomyomatosis. Chest 133(2):448\u2013454. Erratum in: Chest. 2009;136:653. doi: 10.1378\/chest.07-2277","DOI":"10.1378\/chest.07-2277"},{"key":"9742_CR37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1590\/S1806-37132011000300015","volume":"37","author":"BG Baldi","year":"2011","unstructured":"Baldi BG, Medeiros P, Junior Pimenta SP, Lopes RI, Kairalla RA, Carvalho CR (2011) Evolution of pulmonary function after treatment with goserelin in patients with lymphangioleiomyomatosis. J Bras Pneumol 37:375\u2013379. doi: 10.1590\/S1806-37132011000300015","journal-title":"J Bras Pneumol"},{"key":"9742_CR38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1183\/09059180.00008813","volume":"23","author":"S El-Chemaly","year":"2014","unstructured":"El-Chemaly S, Henske EP (2014) Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer. Eur J Respir 23:30\u201335. doi: 10.1183\/09059180.00008813","journal-title":"Eur J Respir"},{"key":"9742_CR39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1084\/jem.20131080","volume":"211","author":"Ch Li","year":"2014","unstructured":"Li Ch, Lee PS, Sun Y, Gu X et al (2014) Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med 211:15\u201328. doi: 10.1084\/jem.20131080","journal-title":"J Exp Med"},{"key":"9742_CR40","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","volume":"364","author":"FX McCormack","year":"2011","unstructured":"McCormack FX, Inoue Y, Moss J et al (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364:1595\u20131606. doi: 10.1056\/NEJMoa1100391","journal-title":"N Engl J Med"},{"key":"9742_CR41","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2213-2600(13)70090-0","volume":"1","author":"LR Young","year":"2013","unstructured":"Young LR, Lee HS, Inoune Y et al (2013) Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of Multicentre International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med 1:445\u2013452. doi: 10.1016\/S2213-2600(13)70090-0","journal-title":"Lancet Respir Med"},{"key":"9742_CR42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler JJ, McCormack FX, Young LR et al (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358:140\u2013151. doi: 10.1056\/NEJMoa063564","journal-title":"N Engl J Med"},{"key":"9742_CR43","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","volume":"17","author":"DM Davies","year":"2011","unstructured":"Davies DM, de Dries PJ, Johnson SR et al (2011) Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 17:4071\u20134081","journal-title":"Clin Cancer Res"},{"key":"9742_CR44","doi-asserted-by":"crossref","first-page":"797","DOI":"10.7326\/0003-4819-154-12-201106210-00007","volume":"154","author":"AM Taveira-DaSilva","year":"2011","unstructured":"Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J (2011) Changes in lung function and chylous effusion in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Int Med 154:797\u2013805. doi: 10.7326\/0003-4819-154-12-201106210-00007","journal-title":"Ann Int Med"},{"issue":"3","key":"9742_CR45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.resinv.2013.03.002","volume":"51","author":"K Ando","year":"2013","unstructured":"Ando K, Kataoka H, Ueyama M et al (2013) The efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis. Respir Inv 51(3):175\u2013183. doi: 10.1016\/j.resinv.2013.03.002","journal-title":"Respir Inv"},{"key":"9742_CR46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1465-9921-12-66","volume":"12","author":"C Neurohr","year":"2011","unstructured":"Neurohr C, Hoffmann AL, Huppmann P et al (2011) Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis. Respir Res 12:66. doi: 10.1186\/1465-9921-12-66","journal-title":"Respir Res"},{"issue":"1","key":"9742_CR47","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1164\/rccm.201405-0918OC","volume":"190","author":"J Yao","year":"2014","unstructured":"Yao J, Taveira-DaSilva AM, Jones AM, Julien-Williams P, Stylianou M, Moss J (2014) Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis. Am J Respir Crit Care Med 190(1):1273\u20131282. doi: 10.1164\/rccm.201405-0918OC","journal-title":"Am J Respir Crit Care Med"},{"key":"9742_CR48","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1586\/era.11.93","volume":"11","author":"DN Franz","year":"2011","unstructured":"Franz DN (2011) Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. Expert Rev Anticancer Ther 11:1181\u20131192. doi: 10.1586\/era.11.93","journal-title":"Expert Rev Anticancer Ther"},{"key":"9742_CR49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN, Belousova E, Sparagana S et al (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381:125\u2013132. doi: 10.1016\/S0140-6736(12)61134-9","journal-title":"Lancet"},{"key":"9742_CR50","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ, Kingswood JCh, Radzikowska E et al (2013) Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381:817\u2013824. doi: 10.1016\/S0140-6736(12)61767-X","journal-title":"Lancet"},{"key":"9742_CR51","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/ijc.26139","volume":"130","author":"V Makovski","year":"2012","unstructured":"Makovski V, Haklai R, Kloog Y (2012) Farnesylrhiosalicylic acid (salirasib) inhibits Rheb inTSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis. Int J Cancer 130:1420\u20131429. doi: 10.1002\/ijc.26139","journal-title":"Int J Cancer"},{"key":"9742_CR52","author":"N Liang","year":"2014","unstructured":"Liang N, Zhang C, Dill P et al (2014) Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. J Exp Med. doi: 10.1084\/jem.20140341","journal-title":"J Exp Med"},{"key":"9742_CR53","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1165\/rcmb.2013-0203RC","volume":"49","author":"EN Atochina-Vasserman","year":"2013","unstructured":"Atochina-Vasserman EN, Goncharov DA, Volgina AV, Milavec M, James ML, Krymskaya VP (2013) Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling. Am J Respir Cell Mol Biol 49:704\u2013709. doi: 10.1165\/rcmb.2013-0203RC","journal-title":"Am J Respir Cell Mol Biol"},{"key":"9742_CR54","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1183\/09031936.00012709","volume":"34","author":"S El-Chemaly","year":"2009","unstructured":"El-Chemaly S, Taveira-DaSilva A, Stylianou P, Moss J (2009) Statins in lymphangioleiomyomatosis: a word of caution. Eur Respir J 34:513\u2013514. doi: 10.1183\/09031936.00012709","journal-title":"Eur Respir J"},{"key":"9742_CR55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2210-9-8","volume":"9","author":"N Lee","year":"2009","unstructured":"Lee N, Woodrum CL, Nobil AM, Raukrys AE, Messina MP, Dabora SL (2009) Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol 9:8. doi: 10.1186\/1471-2210-9-8","journal-title":"BMC Pharmacol"},{"key":"9742_CR56","doi-asserted-by":"crossref","first-page":"797","DOI":"10.7326\/0003-4819-154-12-201106210-00007","volume":"154","author":"AM Taveira-DaSilva","year":"2011","unstructured":"Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J (2011) Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med 154:797\u2013805. doi: 10.7326\/0003-4819-154-12-201106210-00007","journal-title":"Ann Intern Med"},{"key":"9742_CR57","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1378\/chest.14-0758","volume":"147","author":"AM Taveira-DaSilva","year":"2015","unstructured":"Taveira-DaSilva AM, Jones AM, Julien-Williams P, Stylianou M, Moss J (2015) Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosis. Chest 147:180\u2013187. doi: 10.1378\/chest.14-0758","journal-title":"Chest"},{"key":"9742_CR58","doi-asserted-by":"crossref","first-page":"267","DOI":"10.5858\/2000-124-0267-RFAOMM","volume":"124","author":"K Matsui","year":"2000","unstructured":"Matsui K, Takeda K, Yu ZX, Travis WD, Moss J, Ferrans VJ (2000) Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 124:267\u2013275","journal-title":"Arch Pathol Lab Med"},{"key":"9742_CR59","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1476-5381.2011.01344.x","volume":"164","author":"LM Moir","year":"2011","unstructured":"Moir LM, Ng HY, Poniris MH et al (2011) Doxycycline inhibits matrix metalloproteinase-2 secretion from TSC2-null mouse embryonic fibroblasts and lymphangioleiomyomatosis cells. Br J Pharmacol 164:83\u201392. doi: 10.1111\/j.1476-5381.2011.01344.x","journal-title":"Br J Pharmacol"},{"key":"9742_CR60","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1152\/ajplung.00437.2009","volume":"299","author":"WY Chang","year":"2010","unstructured":"Chang WY, Clements D, Johnson SR (2010) Effect of doxycycline on proliferation, MMP production, and adhesion in LAM-related cells. Am J Physiol Lung Cell Mol Physiol 299:393\u2013400. doi: 10.1152\/ajplung.00437.2009","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"9742_CR61","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1056\/NEJMc053410","volume":"354","author":"MA Moses","year":"2006","unstructured":"Moses MA, Harper J, Folkman J (2006) Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med 354:2621\u20132622. doi: 10.1056\/NEJMc053410","journal-title":"N Engl J Med"},{"key":"9742_CR62","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1210\/jc.2007-1283","volume":"93","author":"MK Glassberg","year":"2008","unstructured":"Glassberg MK, Elliot SJ, Fritz J et al (2008) Activation of the estrogen receptor contributes to the progression of pulmonary lymphangioleiomyomatosis via matrix metalloproteinase-induced cell invasiveness. J Clin Endocrinol Metab 93:1625\u20131633. doi: 10.1210\/jc.2007-1283","journal-title":"J Clin Endocrinol Metab"},{"key":"9742_CR63","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1590\/S1806-37132013000100002","volume":"39","author":"SP Pimenta","year":"2013","unstructured":"Pimenta SP, Baldi BG, Kairalla RA, Carvalho CRR (2013) Doxycycline use in patients with lymphangioleiomyomatosis: biomarkers and pulmonary response. J Bras Pneumol. 39:5\u201315","journal-title":"J Bras Pneumol."},{"key":"9742_CR64","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1183\/09031936.00167413","volume":"43","author":"WY Chang","year":"2014","unstructured":"Chang WY, Cane JL, Kumaran M, Lewis S, Tattersfield AE, Johnson SR (2014) A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis. Eur Respir J 43:1114\u20131123. doi: 10.1183\/09031936.00167413","journal-title":"Eur Respir J"},{"key":"9742_CR65","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1124\/mol.107.040824","volume":"73","author":"EA Goncharova","year":"2008","unstructured":"Goncharova EA, Goncharov DA, Chisolm A et al (2008) Interferon beta augments tuberous sclerosis complex-2(TSC-2)dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation. Mol Pharmacol 73:778\u2013788. doi: 10.1124\/mol.107.040824","journal-title":"Mol Pharmacol"},{"key":"9742_CR66","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9:153\u2013166. doi: 10.1038\/nrc2602","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"9742_CR67","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4161\/cbt.19589","volume":"13","author":"M Canavese","year":"2012","unstructured":"Canavese M, Santo L, Raje N (2012) Cyclin dependent kinases in cancer potential for therapeutic intervention. Cancer Biol Ther 13(7):451\u2013457. doi: 10.4161\/cbt.19589","journal-title":"Cancer Biol Ther"},{"key":"9742_CR68","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1513\/pats.200909-104JS","volume":"7","author":"J Yu","year":"2010","unstructured":"Yu J, Parkhitko AA, Henske EP (2010) Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy. Proc Am Thorac Soc 7:48\u201353. doi: 10.1513\/pats.200909-104JS","journal-title":"Proc Am Thorac Soc"},{"key":"9742_CR69","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.2353\/ajpath.2009.090525","volume":"175","author":"J Klarquist","year":"2009","unstructured":"Klarquist J, Barfuss A, Kandala S et al (2009) Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells. Am J Pathol 175:2463\u20132472. doi: 10.2353\/ajpath.2009.090525","journal-title":"Am J Pathol"},{"key":"9742_CR70","author":"Y Sun","year":"2014","unstructured":"Sun Y, Gallacchi D, Zhang EY et al (2014) Rapamycin-resistant PARP1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis (LAM). Am J Respir Cell Mol Biol. doi: 10.1165\/rcmb.2104-0033OC","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"8","key":"9742_CR71","doi-asserted-by":"crossref","first-page":"e105365","DOI":"10.1371\/journal.pone.0105365","volume":"9","author":"N Banville","year":"2014","unstructured":"Banville N, Burgess JK, Jaffar J, Tjin G, Richeldi L, Cerri S, Persiani E, Black JL, Oliver BG (2014) A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM). PLoS ONE 9(8):e105365. doi: 10.1371\/journal.pone.0105365","journal-title":"PLoS ONE"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-015-9742-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00408-015-9742-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-015-9742-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:40:48Z","timestamp":1748392848000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00408-015-9742-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,17]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["9742"],"URL":"https:\/\/doi.org\/10.1007\/s00408-015-9742-6","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"type":"print","value":"0341-2040"},{"type":"electronic","value":"1432-1750"}],"subject":[],"published":{"date-parts":[[2015,5,17]]}}}